Antidepressant Suicidality Needs Interim Risk Management, FDAer Maintains
Executive Summary
FDA should establish an interim risk management plan to discourage pediatric antidepressant use, FDA epidemiologist Andrew Mosholder, MD, maintained in an Aug. 16 memo
You may also be interested in...
Antidepressant Fallout Includes Change In FDA Pediatric Study Procedure
Studies conducted under the Best Pharmaceuticals for Children Act will be included in labeling, FDA Office of Medical Policy Director Robert Temple, MD, told the House Energy & Commerce/Oversight Subcommittee Sept. 23
Antidepressant Fallout Includes Change In FDA Pediatric Study Procedure
Studies conducted under the Best Pharmaceuticals for Children Act will be included in labeling, FDA Office of Medical Policy Director Robert Temple, MD, told the House Energy & Commerce/Oversight Subcommittee Sept. 23
FDA Will Strengthen Antidepressant Warnings; “Black Box” Not Certain
FDA will require stronger warnings on antidepressants regarding the risk of pediatric suicidality following a Sept. 13-14 advisory committee review of the issue, but the agency is not yet ready to say that a "black box" will be necessary